BLTE vs. PRTA, XNCR, MNKD, MIRM, ABVX, ABCL, GMTX, LQDA, COLL, and DCPH
Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Prothena (PRTA), Xencor (XNCR), MannKind (MNKD), Mirum Pharmaceuticals (MIRM), ABIVAX Société Anonyme (ABVX), AbCellera Biologics (ABCL), Gemini Therapeutics (GMTX), Liquidia (LQDA), Collegium Pharmaceutical (COLL), and Deciphera Pharmaceuticals (DCPH). These companies are all part of the "pharmaceutical preparations" industry.
Prothena (NASDAQ:PRTA) and Belite Bio (NASDAQ:BLTE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.
Prothena presently has a consensus target price of $68.14, indicating a potential upside of 231.43%. Belite Bio has a consensus target price of $44.83, indicating a potential upside of 20.29%. Given Belite Bio's higher possible upside, equities research analysts clearly believe Prothena is more favorable than Belite Bio.
97.1% of Prothena shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 28.2% of Prothena shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Belite Bio has a net margin of 0.00% compared to Belite Bio's net margin of -160.91%. Belite Bio's return on equity of -24.84% beat Prothena's return on equity.
Prothena received 578 more outperform votes than Belite Bio when rated by MarketBeat users. However, 95.24% of users gave Belite Bio an outperform vote while only 70.60% of users gave Prothena an outperform vote.
In the previous week, Prothena had 1 more articles in the media than Belite Bio. MarketBeat recorded 3 mentions for Prothena and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.50 beat Prothena's score of -0.06 indicating that Prothena is being referred to more favorably in the media.
Belite Bio has lower revenue, but higher earnings than Prothena. Belite Bio is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
Prothena has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.62, meaning that its share price is 262% less volatile than the S&P 500.
Summary
Prothena beats Belite Bio on 11 of the 17 factors compared between the two stocks.
Get Belite Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Belite Bio Competitors List
Related Companies and Tools
